MiNK Therapeutics, Inc.

Good morning and welcome to Mink Therapeutics' second quarter 2024 conference call and webcast. All participants will be in listen-only mode until question and answer session. Please note this event is being recorded. If anyone has any objection, you may now disconnect at this time.

I would now like to turn the conference over to Carmen from Mr. Relations. Thank you all for joining us today. Today's call is being webcast and will be available on our website for replay.

I'd like to remind including statements regarding our clinical development, regulatory and commercial plans and timelines, as well as timelines for data release and partnership opportunities, among other updates. These statements are subject to risks and uncertainties, and we refer you to our SEC filings available on our website for more details on these risks. Joining me today are Dr. Jen Buell, President and Chief Executive Officer, Dr. Mark Van Dyke, Chief Scientific Officer, Dr. Joy Zhao, Head of CMC, and Christine Klaskin, Principal Financial and Accounting Officer. Now, I'd like to turn the call over to Dr. Buell to highlight our progress on this board.